BenzingaSeptember 24, 2026 at 5:27 AM NYLast Month
RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
